Market Overview

September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.


National securities litigation law firm Glancy
Prongay & Murray LLP
("GPM") reminds investors of the September
17, 2018 
deadline to file a lead plaintiff motion in the class
action filed on behalf of investors that purchased ACADIA
Pharmaceuticals Inc. ("ACADIA" or the "Company) (NASDAQ: ACAD)
securities between April 29, 2016 and July 9, 2018, inclusive
(the "Class Period"). ACADIA investors have until September 17,
to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here
to participate.

Investors suffering losses on their ACADIA investments are encouraged to
contact Lesley Portnoy of GPM to discuss their legal rights in this
class action at 310-201-9150 or by email to

On April 9, 2018, CNN reported that "[p]hysicians, medical researchers
and other experts told CNN that they worried that [NUPLAZID] had been
approved too quickly, based on too little evidence that it was safe or
effective. And given these mounting reports of deaths, they say that
more needs to be done to assess Nuplazid's true risks." On this news,
ACADIA's share price fell $5.03 per share, or 23.4%, to close at $16.50
per share on April 9, 2018, thereby injuring investors.

The complaint filed in this class action alleges that, throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company's business, operations, and prospects. Specifically,
Defendants failed to disclose: (1) that adverse events and safety
concerns related to NUPLAZID threatened the drug's initial and
continuing FDA approval; (2) that ACADIA engaged in business practices
likely to attract regulatory scrutiny; and (3) that, as a result of the
foregoing, Defendants' statements about ACADIA's business, operations,
and prospects were materially false and/or misleading and/or lacked a
reasonable basis.

Follow us for updates on Twitter:

If you purchased shares of ACADIA during the Class Period you may move
the Court no later than September 17, 2018 to ask the
Court to appoint you as lead. To be a member of the Class you need not
take any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, at 310-201-9150,
Toll-Free at 888-773-9224, by email to,
or visit our website at
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!